Brain & Spinal Cord Cancer Market by Tumor Type (Glioblastoma, Meningioma, Pituitary Tumors), Treatment (Diagnosis, Therapeutics), End-users - Global Forecast 2024-2030

Brain & Spinal Cord Cancer Market by Tumor Type (Glioblastoma, Meningioma, Pituitary Tumors), Treatment (Diagnosis, Therapeutics), End-users - Global Forecast 2024-2030

The Brain & Spinal Cord Cancer Market size was estimated at USD 3.77 billion in 2023 and expected to reach USD 3.98 billion in 2024, at a CAGR 5.75% to reach USD 5.59 billion by 2030.

Brain and spinal cord cancers are types of central nervous system cancers that occur when malignant (cancer) cells grow in the brain or spinal cord tissue. These cancers can disrupt the vital functions controlled by these areas, including muscle control, sensation, memory, and other cognitive abilities. Treatment plans for brain and spinal cord cancers are tailored to each individual's specific condition and may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these. This market's applications span across various medical fields, including neuro-oncology, neurosurgery, radiology, and palliative care. End-users are typically healthcare facilities such as hospitals, clinics, and specialized cancer treatment centers, besides patients requiring diagnostic, therapeutic, and supportive care services. Factors influencing the need for brain and spinal cord cancer treatment include advancements in medical technology, rising prevalence of brain and spinal cord cancers, increased investment in healthcare infrastructure, and awareness about these conditions. However, the market faces certain challenges, such as high treatment costs, limited accessibility to advanced healthcare facilities, and concerns associated with the complex nature of brain and spinal cord cancers. On the other hand, the incorporation of AI and machine learning in diagnostic processes and increasing preference for personalized medicine based on genetic profile present potential opportunities for the brain and spinal cord cancers market.

Regional Insights

In the Americas, particularly in the United States and Canada, significant investments in research and development have been made to advance the treatment of brain and spinal cord cancers. High healthcare expenses and the presence of major healthcare institutions and biotech firms have propelled advanced research initiatives, including precision medicine and novel therapeutics. In South America, Brazil and Argentina are witnessing moderate development in the treatment of the brain and spinal cord cancer market due to rising healthcare expenditure, increasing incidence of cancer, and gradual improvements in healthcare infrastructure. The EU countries boast a robust healthcare infrastructure and several ongoing initiatives for cancer research and early detection. Increased funding from both public and private sectors towards healthcare research has led to significant breakthroughs. Patients in this region benefit from universal healthcare systems, influencing their ability to access advanced treatments. The Middle East and Africa region encounters unique challenges, including variable healthcare infrastructure and accessibility issues. The focus is gradually shifting towards improving healthcare facilities and cancer care centers, with several governments and NGOs playing a pivotal role. The APAC region is witnessing a rapid transformation in the healthcare sector, driven by growing economies such as China, Japan, and India. These countries have seen a surge in healthcare spending and are at the forefront of technological innovation in cancer treatment. Consumer awareness and demand for quality cancer care are high, leading to greater government and private investment in healthcare infrastructure and research initiatives.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Brain & Spinal Cord Cancer Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Rising prevalence of brain and spinal cord cancers globally
• Increased investment in healthcare infrastructure with growing awareness about these conditions
• Ongoing government initiatives aimed at cancer research and early detection

Market Restraints

• High treatment costs and limited accessibility to advanced healthcare facilities for brain and spinal cord cancer

Market Opportunities

• Incorporation of AI and machine learning in diagnostic processes
• Increasing preference for personalized medicine based on genetic profile

Market Challenges

• Concerns associated with the complex nature of brain and spinal cord cancers

Market Segmentation Analysis

• Treatment:
• End-users:

Market Disruption Analysis

• Porter’s Five Forces Analysis
• Value Chain & Critical Path Analysis
• Pricing Analysis
• Technology Analysis
• Patent Analysis
• Trade Analysis
• Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Brain & Spinal Cord Cancer Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Brain & Spinal Cord Cancer Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Diakonos’ brain tumor vaccine receives FDA’s orphan drug designation

The U.S. Food and Drug Administration (FDA) awarded Diakonos' dendritic cell vaccine, DOC1021, with orphan drug designation for its potential use in treating malignant glioma, specifically targeting newly diagnosed or refractory glioblastoma multiforme. This designation could pave the way for up to seven years of exclusive market rights following approval and tax benefits for domestic clinical trials.

Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

Novartis AG received the U.S. Food and Drug Administration's approval of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for pediatric patients aged one year and above diagnosed with BRAF V600E mutation-positive low-grade glioma (LGG) requiring systemic therapy.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Brain & Spinal Cord Cancer Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Brain & Spinal Cord Cancer Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Bayer AG, bluebird bio, Inc., Bristol Myers Squibb Company, Dr. Reddy’s Laboratories Ltd., Eisai Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, Illumina, Inc., Johnson & Johnson Services, Inc, Merck & Co., Inc., Nektar Therapeutics, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Shimadzu Corporation, Siemens Healthineers, Teva Pharmaceutical Industries Ltd., and Y-mAbs Therapeutics A/S.

Market Segmentation & Coverage

This research report categorizes the Brain & Spinal Cord Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Tumor Type
• Glioblastoma
• Meningioma
• Pituitary Tumors
• Treatment
• Diagnosis
• Cerebral Arteriogram
• CT Scan
• EEG
• Lumbar Puncture
• Molecular Testing
• MRI
• PET-CT Scan
• Tissue Sampling
• Therapeutics
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• Targeted Therapy
• End-users
• Ambulatory Surgical Centers
• Diagnostic Centers
• Hospital & Clinics

Region

• Americas
• Argentina
• Brazil
• Canada
• Mexico
• United States
• California
• Florida
• Illinois
• New York
• Ohio
• Pennsylvania
• Texas
• Asia-Pacific
• Australia
• China
• India
• Indonesia
• Japan
• Malaysia
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• Europe, Middle East & Africa
• Denmark
• Egypt
• Finland
• France
• Germany
• Israel
• Italy
• Netherlands
• Nigeria
• Norway
• Poland
• Qatar
• Russia
• Saudi Arabia
• South Africa
• Spain
• Sweden
• Switzerland
• Turkey
• United Arab Emirates
• United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year